Fenofibrate can reduce the incidence of coronary heart disease events, but has little effect on stabilizing plaque, the specific use of medication as prescribed by the doctor. Fenofibrate has the effect of lowering cholesterol and triglyceride, antiplatelet aggregation, lowering uric acid, etc. It is suitable for hyperlipidemia that is not satisfactory by diet control therapy, in which the effect of lowering triglyceride and mixed hyperlipidemia is better. Fenofibrate has not been shown to reduce all-cause mortality in the primary or secondary prevention of cardiovascular disease, and there is no direct evidence that it can stabilize or even reverse plaque. Contraindications include hypersensitivity to the product or to fenofibrate acid, combination with other fibrates, known gallbladder disease, severe renal insufficiency (including those on dialysis), phototoxicity or photosensitization following administration of the product or other structurally similar drugs (especially ketoprofen), active liver disease, children, pregnant women, and breastfeeding women. Adverse reactions such as headache, abdominal pain, back pain, nausea, constipation, elevated ghrelin or ghrelin, rhinitis, etc. may occur after use of the drug. The specific use of the drug in question should be under the guidance of a specialist and should not be self-administered.